Assembly Biosciences Inc. (NASDAQ:ASMB) was up 8% on Friday . The stock traded as high as $6.51 and last traded at $6.50, with a volume of 52,032 shares. The stock had previously closed at $6.02.

Separately, William Blair started coverage on shares of Assembly Biosciences in a research report on Friday. They issued an “outperform” rating for the company.

The firm has a 50 day moving average of $5.95 and a 200-day moving average of $5.56. The company’s market capitalization is $112.65 million.

An institutional investor recently raised its position in Assembly Biosciences stock. Jennison Associates LLC increased its stake in shares of Assembly Biosciences Inc. (NASDAQ:ASMB) by 0.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,025,870 shares of the biopharmaceutical company’s stock after buying an additional 6,486 shares during the period. Jennison Associates LLC owned approximately 11.76% of Assembly Biosciences worth $15,214,000 as of its most recent filing with the SEC.

Assembly Biosciences, Inc (Assembly) is a biopharmaceutical company. The Company is engaged in the development of oral therapies for the cure of intractable infectious diseases, focusing on hepatitis B virus (HBV) and clostridium (C.) difficile-associated infections (CDAD). The target of Assembly’s lead program is a clinical cure for HBV, for , which it is developing a series of compounds, known as core protein allosteric modulators (CpAMs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.